phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers

Journal of Infectious Diseases

Volumn 173, Issue 6, 1996, Pages 1408-1414

  Hohmann, Elizabeth L ^a   Oletta, Carmen A ^c   Killeen, Kevin P ^c   Miller, Samuel I ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVE VACCINE; O ANTIGEN; TYPHOID VACCINE;

ACUTE GASTROENTERITIS; ADULT; ARTICLE; BACTERIAL VIRULENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; FEVER; GENE DELETION; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOGENICITY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REGULATOR GENE; SALMONELLA TYPHI; TYPHOID FEVER; VACCINATION; VOLUNTEER;

EID: 0029799771     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.6.1408     Document Type: Article

References (31)

1. Levine MM, Fereccio C, Black RE, Tacket CO, Germainer R. Progress in vaccines against typhoid fever. Rev Infect Dis 1989;11(suppl 3): S552-67.
2. Levine MM. Typhoid fever vaccines. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. Philadelphia: WB Saunders, 1994:597-633.
3. Hirschell B, Wuthrick R, Somaini B, Staffen R. Inefficacy of the commercial live oral Ty21a vaccine in the prevention of typhoid fever. Eur J Clin Microbiol 1986;4:925-8.
4. Schwartz E, Shlim RR, Eaton M, Jenks N, Houston R. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal. Arch Intern Med 1990; 150:349-51.
5. Gonzales C, Hone D, Noriega FR, et al. Salmonella typhi vaccine strain CVD908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis 1994; 169:927-31.
6. Levine MM, Herrington D, Murphy MR, et al. Safety, infectivity, immunogenicity and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi 541Ty and 543Ty, as live oral vaccines in man. J Clin Invest 1987;79:888-902.
7. Tacket CO, Hone DM, Curtiss R III, et al. Comparison of the safety and immunogenicity of ΔaroCΔaroD and ΔcyaΔcrp S. typhi strains in adult volunteers. Infect Immun 1992;60:536-41.
8. Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, Levine MM. Clinical acceptability of CVD 908 Salmonella typhi vaccine strain. Vaccine 1992; 10:443-6.
9. Miller SI, Kukral AM, Mekalanos JJ. A two component regulatory system phoP phoQ controls Salmonella typhimurium virulence. Proc Natl Acad Sci USA 1989; 86:5054-8.
10. Groisman E, Chiao E, Lipps C, Heffron F. Salmonella typhimurium phoP virulence gene is a transcriptional regulator. Proc Natl Acad Sci USA 1989; 86:7077-81.
11. Beiden WJ, Miller SI. Further characterization of the PhoP regulon: identification of new pag virulence loci. Infect Immun 1994;62:5095-101.
12. Behlau I, Miller S. A PhoP-repressed gene promotes S. typhimurium invasion of epithelial cells. J Bacteriol 1993; 175:4475-84.
13. Pulkkinen W, Miller S. A S. typhimurium virulence protein is similar to a Yersinia enterocolitica invasion protein and a bacteriophage lambda outer membrane protein. J Bacteriol 1991; 173:86-93.
14. Fields P, Groisman E, Heffron F. A Salmonella locus that controls resistance to microbicidal proteins from phagocytic cells. Science 1986; 243: 1059-62.
15. Miller SI, Pulkkinen WS, Selsted ME, Mekalanos JJ. Characterization of defensin resistance phenotypes associated with mutations in the phoP virulence regulon of Salmonella typhimurium. Infect Immun 1990;58: 3706-10.
16. Galán JE, Curtiss R III. Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microb Pathog 1989;6:433-43.
17. Miller SI, Mekalanos JJ, Pulkkinen WS. Salmonella vaccines with mutations in the phoP virulence regulon. Res Microbiol 1990;141:817-21.
18. Hohmann EL, Oletta CA, Miller SI. Evaluation of a phoP/phoQ-deleted aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 1995;14:19-24.
19. Blofield I, Vaughn V, Rest R, Eisenstein B. Allelic exchange in E. coli using the Bacillus subtilis sacB gene and a temperature sensitive pSC101 replicon. Mol Microbiol 1991;5:1447-57.
20. Donnenberg M, Kaper J. Construction of an eae deletion mutant of entero-pathogenic E. coli by using a positive-selection suicide vector. Infect Immun 1991;59:4310-7.
21. Kier LD, Weppelman RM, Ames BN. Regulation of nonspecific acid phosphatase in Salmonella: phoN and phoP genes. J Bacteriol 1979; 138:155-61.
22. Forrest BD. Identification of an intestinal immune response using peripheral blood lymphocytes. Lancet 1988;1:81-3.
23. Kantele A, Arvilommi H, Jokinen I. Specific immunoglobulin secreting human blood cells after peroral vaccination against S. typhi. J Infect Dis 1986;153:1126-31.
24. Levine MM, Kaper J, Herrington D, et al. Safety, immunogenicity and efficacy of recombinant live oral cholera vaccine CVD 103 and CVD 103-HgR. Lancet 1988;2:467-70.
25. Forrest BD, Labrooy JT, Beyer L, Dearlove CE, Shearson DJC. The human humoral immune response to Salmonella typhi Ty21a. J Infect Dis 1991; 163:336-45.
26. Hoffmann E, Chianale J, Rollán A, Pereira J, Ferrecio C, Sotomayor V. Blood group antigen secretion and gallstone disease in the Salmonella typhi chronic carrier state [letter]. J Infect Dis 1993;167:993-4.
27. Forrest BD. Indirect measurement of intestinal immune responses to an orally administered attenuated bacterial vaccine. Infect Immun 1992; 60:2023-9.
28. Tacket CO, Losonsky G, Taylor DM, et al. Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies. J Infect Dis 1991;163: 901-4.
29. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-98.
30. Forrest BD. Impairment of immunogenicity of Salmonella typhi Ty21a due to preexisting cross-reacting intestinal antibodies [letter]. J Infect Dis 1992;166:210-2.
31. Wick M, Harding CV, Twesten NJ, Normark SJ, Pfeifer JD. The phoP locus influences processing and presentation of 5. typhimurium antigens by activated macrophages. Mol Microbiol 1995;16:465-70.